to-BBB (NL)

to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for devastating brain disorders by combining existing drugs with the G-Technology®, to-BBB’s proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. to-BBB is currently testing its internal lead product 2B3-101 for brain cancer in a clinical phase I/II trial.